News Channels

05 Dec 2019 Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%
05 Dec 2019 Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
05 Dec 2019 ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
05 Dec 2019 Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
04 Dec 2019 Innovative Cellular Therapeutics Announces FDA Clearance of IND for its Dominant Negative PD-1 “Armored” Next Generation CAR-T Cell Therapy
04 Dec 2019 Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
04 Dec 2019 Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
04 Dec 2019 Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
04 Dec 2019 Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant
04 Dec 2019 Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
04 Dec 2019 Bio-Thera Solutions Announces NMPA approval of IND Application to Initiate Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
04 Dec 2019 ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superagonist in Non-Muscle Invasive Bladder Cancer
04 Dec 2019 Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
04 Dec 2019 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
04 Dec 2019 BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A
04 Dec 2019 Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
04 Dec 2019 Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
04 Dec 2019 Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
04 Dec 2019 Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
04 Dec 2019 Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top